A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD
Latest Information Update: 19 Sep 2024
At a glance
- Drugs WVE-004 (Primary)
- Indications Amyotrophic lateral sclerosis; Frontotemporal dementia
- Focus Adverse reactions
- Sponsors WaVe life Sciences
Most Recent Events
- 18 Oct 2023 Status changed from recruiting to discontinued.
- 17 Jul 2023 This trial has been completed in Ireland (End Date: 30 Jun 2023), according to European Clinical Trials Database record.
- 13 Jun 2023 This trial has been discontinued in Ireland and Netherlands, according to European Clinical Trials Database record.